Twitter | Pretraživanje | |
Pretraživanje Osvježi
Pavan 18 h
Interested candidates can ping me @ Hetero Biopharma
Reply Retweet Označi sa "sviđa mi se"
PepGra CRO 27 min
Guideline on adjustment for baseline covariates in clinical trials | Reason for using stratified designs - 
Reply Retweet Označi sa "sviđa mi se"
OncLive.com 3 h
. of discusses the emergence of in oncology and how he anticipates they will change the paradigm
Reply Retweet Označi sa "sviđa mi se"
Key Biologics, LLC 7 h
BREAKING: ⁦⁩ announces spin-off company + new HQ in New Jersey near parent campus. 75% of new co.’s sales expected to come from outside U.S. & involve 10k-11k employees under direction of new spin-off CEO Kevin Ali, a 30-yr. Merck veteran.
Reply Retweet Označi sa "sviđa mi se"
AAM 8 h
How much does your state save? In 2018, generic prescription medicines saved $6.4B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved:
Reply Retweet Označi sa "sviđa mi se"
Larry Abrams 8 h
Odgovor korisniku/ci @kshahi
check out my latest post on spin out of hodge-podge product lines including licensed from Samsung Bioepis. Would make sense for to do another spinout of then do a M&E with with better marketing org. Eliminate duplicate R&D.
Reply Retweet Označi sa "sviđa mi se"
Larry Abrams 8 h
-- new hodge-podge spin out includes marketing org for drugs licensed from Samsung Bioepis. Would make sense for further spin out of pure co and buy with better marketing org. Eliminate duplicate R&D (even I can make a bull case for )
Reply Retweet Označi sa "sviđa mi se"
Larry Abrams 12 h
Odgovor korisniku/ci @kshahi
are much much harder to manufacturing than small molecule generics. Tossing off an FDA identified issue with newbie European partner’s contract manufacturer process, however small, as “growing pains” ignores fact that patients’ lives are at stake here.
Reply Retweet Označi sa "sviđa mi se"
Crohn's and Colitis Canada 12 h
Looking for information about and ? Take a peek at our sheet, and learn why we advocate for patient-doctor choice 👨‍⚕️🏥👩‍⚕️.
Reply Retweet Označi sa "sviđa mi se"
WT Farma 13 h
Alternate title: : Let's not f*** this up
Reply Retweet Označi sa "sviđa mi se"
Stanton Mehr 14 h
Do you ever wonder where the US market is heading, and when it might get there? I've just finished a report that answers this exact question! For drug makers, payers, prescribers, policymakers, and anyone involved in the industry.
Reply Retweet Označi sa "sviđa mi se"
Teva Pharmaceuticals 15 h
Go Behind the Scenes at Teva’s state-of-the-art facility in Ulm, Germany, and meet the experts who are advancing more treatment options for patients
Reply Retweet Označi sa "sviđa mi se"
Neethu Sreenivasan 16 h
Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and into New Company (“NewCo”)
Reply Retweet Označi sa "sviđa mi se"
Euro Biosimilars_2020 16 h
Having an intention to prove yourself to the world? Let's Euro Biosimilars 2020 learn and Explore . for . YoungResearcher #2020
Reply Retweet Označi sa "sviđa mi se"
En-CPhI.cn 5. velj
China’s Biosimilars Commercialized at an Impressive Speed. A comparison of the biosimilar accessibility in China, the EU, and the U.S.
Reply Retweet Označi sa "sviđa mi se"
Stanton Mehr 4. velj
FDA and FTC Say They Will Work Collaboratively to Deter Anticompetitive Behavior: Actions Speak Louder Than Words
Reply Retweet Označi sa "sviđa mi se"
ThePharmaLetter 4. velj
. and talk tough on ensuring competition for biologics
Reply Retweet Označi sa "sviđa mi se"
Larry Abrams 3. velj
Odgovor korisniku/ci @ihdezdelso @walidgellad i 3 ostali
IMHO, your paper is the most important paper on in 2019. It is THE counter to argument for heavy regulation (vs competition) of a biologic therapeutic class once the reference drug loses it patents.
Reply Retweet Označi sa "sviđa mi se"
Larry Abrams 3. velj
Odgovor korisniku/ci @SteveFDA @USBiosimilars i 2 ostali
You state that are list priced 15% to 35% less than reference drug...implying that are cheaper than reference drugs. You should do more work on getting comparisons of net prices after rebates in the commercial market and report on that
Reply Retweet Označi sa "sviđa mi se"
SpeedyGonzalesi 1. velj
With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019.
Reply Retweet Označi sa "sviđa mi se"